April 9, 2020 10:13 AM EDT

Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola

ENDPOINTS

→ Ten months after Array showed off the positive BEACON-CRC data that enticed Pfizer to write a $11.4 billion buyout check, the pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola

ENDPOINTS

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Pfiz­er nabs col­orec­tal can­cer OK for Braftovi; Bris­tol My­ers, Pfiz­er pull out of re­gion­al deal with Por­to­la

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pfizer nabs colorectal cancer OK for Braftovi; Bristol Myers, Pfizer pull out of regional deal with Portola